123 related articles for article (PubMed ID: 34281850)
21. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
Faloppi L; Bianconi M; Giampieri R; Sobrero A; Labianca R; Ferrari D; Barni S; Aitini E; Zaniboni A; Boni C; Caprioni F; Mosconi S; Fanello S; Berardi R; Bittoni A; Andrikou K; Cinquini M; Torri V; Scartozzi M; Cascinu S;
Oncotarget; 2015 Oct; 6(33):35087-94. PubMed ID: 26397228
[TBL] [Abstract][Full Text] [Related]
22. Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy.
Wang Y; Xu F; Pan J; Zhu Y; Shao X; Sha J; Wang Z; Cai Y; Liu Q; Dong B; Xue W; Huang Y
BMC Cancer; 2016 May; 16():329. PubMed ID: 27222030
[TBL] [Abstract][Full Text] [Related]
23. Androgen receptor expression in prostate cancer lymph node metastases is predictive of outcome after surgery.
Sweat SD; Pacelli A; Bergstralh EJ; Slezak JM; Cheng L; Bostwick DG
J Urol; 1999 Apr; 161(4):1233-7. PubMed ID: 10081876
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Significance of Preoperative Serum Lactate Dehydrogenase in Upper Urinary Tract Urothelial Carcinoma.
Zhang XK; Zhang ZL; Lu X; Yang P; Cai MY; Hu WM; Yun JP; Zhou FJ; Qian CN; Cao Y
Clin Genitourin Cancer; 2016 Aug; 14(4):341-345.e3. PubMed ID: 26868330
[TBL] [Abstract][Full Text] [Related]
25. Favorable outcomes in locally advanced and node positive prostate cancer patients treated with combined pelvic IMRT and androgen deprivation therapy.
Lilleby W; Narrang A; Tafjord G; Vlatkovic L; Russnes KM; Stensvold A; Hole KH; Tran P; Eilertsen K
Radiat Oncol; 2015 Nov; 10():232. PubMed ID: 26577452
[TBL] [Abstract][Full Text] [Related]
26. The role of adjuvant radiotherapy in pathologically lymph node-positive prostate cancer.
Jegadeesh N; Liu Y; Zhang C; Zhong J; Cassidy RJ; Gillespie T; Kucuk O; Rossi P; Master VA; Alemozaffar M; Jani AB
Cancer; 2017 Feb; 123(3):512-520. PubMed ID: 27859018
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, Cancer Antigen 153 and Cancer Antigen 125 in Metastatic Breast Cancer.
Ma YY; Wang H; Zhao WD; Li YF; Wang JJ; Chen XY; Huang YQ; Wang WJ; Wang Y; Sun SC
Cancer Control; 2022; 29():10732748211053150. PubMed ID: 34989251
[TBL] [Abstract][Full Text] [Related]
28. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
[TBL] [Abstract][Full Text] [Related]
29. Primary site and regional lymph node involvement are independent prognostic factors for early-stage extranodal nasal-type natural killer/T cell lymphoma.
Niu SQ; Yang Y; Li YY; Wen G; Wang L; Li ZM; Wang HY; Zhang LL; Xia YF; Zhang YJ
Chin J Cancer; 2016 Apr; 35():34. PubMed ID: 27044275
[TBL] [Abstract][Full Text] [Related]
30. Clinical features and prognostic factors for patients with bone metastases from prostate cancer.
He J; Zeng ZC; Yang P; Chen B; Jiang W; Du SS
Asian J Androl; 2012 May; 14(3):505-8. PubMed ID: 22504872
[TBL] [Abstract][Full Text] [Related]
31. Serum PSA evaluations during salvage radiotherapy for post-prostatectomy biochemical failures as prognosticators for treatment outcomes.
Do T; Dave G; Parker R; Kagan AR
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1220-5. PubMed ID: 11483332
[TBL] [Abstract][Full Text] [Related]
32. Prostate-Specific Antigen (PSA) Bounce After Dose-Escalated External Beam Radiation Therapy Is an Independent Predictor of PSA Recurrence, Metastasis, and Survival in Prostate Adenocarcinoma Patients.
Romesser PB; Pei X; Shi W; Zhang Z; Kollmeier M; McBride SM; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2018 Jan; 100(1):59-67. PubMed ID: 29254782
[TBL] [Abstract][Full Text] [Related]
33. Prostate-specific antigen/prostatic acid phosphatase ratio is significant prognostic factor in patients with stage IV prostate cancer.
Saito T; Hara N; Kitamura Y; Komatsubara S
Urology; 2007 Oct; 70(4):702-5. PubMed ID: 17991541
[TBL] [Abstract][Full Text] [Related]
34. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
[TBL] [Abstract][Full Text] [Related]
35. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
[TBL] [Abstract][Full Text] [Related]
36. Association between lactate dehydrogenase levels and oncologic outcomes in metastatic prostate cancer: A meta-analysis.
Li F; Xiang H; Pang Z; Chen Z; Dai J; Chen S; Xu B; Zhang T
Cancer Med; 2020 Oct; 9(19):7341-7351. PubMed ID: 32452656
[TBL] [Abstract][Full Text] [Related]
37. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
Buskirk SJ; Pisansky TM; Atkinson EJ; Schild SE; O'Brien PC; Wolfe JT; Zincke H
Mayo Clin Proc; 2001 Jul; 76(7):702-6. PubMed ID: 11444402
[TBL] [Abstract][Full Text] [Related]
38. Prognostic Value of Platelet Counts in Patients with Metastatic Prostate Cancer Treated with Endocrine Therapy.
Shimodaira K; Nakashima J; Nakagami Y; Hirasawa Y; Hashimoto T; Satake N; Gondo T; Namiki K; Ohori M; Ohno Y
Urol J; 2020 Jan; 17(1):42-49. PubMed ID: 30882158
[TBL] [Abstract][Full Text] [Related]
39. Serum interleukin 6 as a prognostic factor in patients with prostate cancer.
Nakashima J; Tachibana M; Horiguchi Y; Oya M; Ohigashi T; Asakura H; Murai M
Clin Cancer Res; 2000 Jul; 6(7):2702-6. PubMed ID: 10914713
[TBL] [Abstract][Full Text] [Related]
40. The prognostic effect of prostate-specific antigen half-life at the first follow-up visit in newly diagnosed metastatic prostate cancer.
Kim KH; Han KS; Kim KH; Kim DK; Koo KC; Rha KH; Choi YD; Hong SJ
Urol Oncol; 2015 Sep; 33(9):383.e17-22. PubMed ID: 26004165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
